ATE324883T1 - Pharmazeutische zusammensetzung enthaltend lumiracoxib - Google Patents

Pharmazeutische zusammensetzung enthaltend lumiracoxib

Info

Publication number
ATE324883T1
ATE324883T1 AT02767455T AT02767455T ATE324883T1 AT E324883 T1 ATE324883 T1 AT E324883T1 AT 02767455 T AT02767455 T AT 02767455T AT 02767455 T AT02767455 T AT 02767455T AT E324883 T1 ATE324883 T1 AT E324883T1
Authority
AT
Austria
Prior art keywords
lumiracoxib
pharmaceutical composition
composition containing
pharmaceutical
containing lumiracoxib
Prior art date
Application number
AT02767455T
Other languages
English (en)
Inventor
Anees Abdulquadar Karnachi
Simon David Bateman
Original Assignee
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh
Application granted granted Critical
Publication of ATE324883T1 publication Critical patent/ATE324883T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02767455T 2001-08-31 2002-08-30 Pharmazeutische zusammensetzung enthaltend lumiracoxib ATE324883T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31638901P 2001-08-31 2001-08-31

Publications (1)

Publication Number Publication Date
ATE324883T1 true ATE324883T1 (de) 2006-06-15

Family

ID=23228840

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02767455T ATE324883T1 (de) 2001-08-31 2002-08-30 Pharmazeutische zusammensetzung enthaltend lumiracoxib

Country Status (29)

Country Link
US (2) US20030114527A1 (de)
EP (1) EP1425005B1 (de)
JP (1) JP4636796B2 (de)
KR (1) KR100895551B1 (de)
CN (1) CN100406008C (de)
AR (1) AR036312A1 (de)
AT (1) ATE324883T1 (de)
AU (1) AU2002331094B2 (de)
BR (1) BR0212155A (de)
CA (1) CA2456604C (de)
CO (1) CO5560554A2 (de)
CY (1) CY1106137T1 (de)
DE (1) DE60211183T2 (de)
DK (1) DK1425005T3 (de)
EC (1) ECSP044986A (de)
ES (1) ES2263813T3 (de)
HU (1) HUP0401429A2 (de)
IL (1) IL160375A0 (de)
MX (1) MXPA04001933A (de)
MY (1) MY137516A (de)
NO (1) NO20040860L (de)
NZ (1) NZ531342A (de)
PE (1) PE20030323A1 (de)
PL (1) PL367464A1 (de)
PT (1) PT1425005E (de)
RU (1) RU2329801C2 (de)
SI (1) SI1425005T1 (de)
WO (1) WO2003020261A1 (de)
ZA (1) ZA200400877B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
EP1492520A1 (de) * 2002-03-07 2005-01-05 Novartis AG Pharmazeutische zusammensetzungen
PL2334378T3 (pl) 2008-08-19 2014-09-30 Xenoport Inc Proleki wodorofumaranu metylu, ich kompozycje farmaceutyczne i sposoby zastosowania
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20140093563A1 (en) * 2011-06-13 2014-04-03 Ranbaxy Laboratories Limited Febuxostat compositions
WO2013172297A1 (ja) 2012-05-14 2013-11-21 塩野義製薬株式会社 6,7-不飽和-7-カルバモイルモルヒナン誘導体含有製剤
US9597292B2 (en) 2012-08-22 2017-03-21 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
JP2015527372A (ja) 2012-08-22 2015-09-17 ゼノポート,インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
RU2712267C2 (ru) * 2014-01-10 2020-01-28 Джонсон энд Джонсон Консьюмер Инк. Способ изготовления таблеток с использованием радиочастотного излучения и частиц с поглощающим покрытием
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
WO2025043076A1 (en) 2023-08-24 2025-02-27 10X Genomics, Inc. Methods, kits, and compositions for spatial detection of genetic variants

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ267417A (en) * 1993-06-08 1997-02-24 Ciba Geigy Ag An inclusion compound of diclofenac and gamma-cyclodextrin and compressed dosage forms thereof
EE03746B1 (et) * 1996-05-17 2002-06-17 Merck & Co., Inc. Farmatseutiline kompositsioon tsüklooksügenaas-2 vahendatud haiguste raviks, 3-fenüül-4-(4-(metüülsulfonüül) fenüül)-2-(5H)-furanooni kasutamine ja ühikuline oraalne doseerimisvorm
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas

Also Published As

Publication number Publication date
CY1106137T1 (el) 2011-06-08
CN100406008C (zh) 2008-07-30
EP1425005B1 (de) 2006-05-03
MY137516A (en) 2009-02-27
KR20040031019A (ko) 2004-04-09
MXPA04001933A (es) 2004-06-15
NZ531342A (en) 2005-09-30
JP2005520785A (ja) 2005-07-14
PL367464A1 (en) 2005-02-21
HK1087336A1 (zh) 2006-10-13
PE20030323A1 (es) 2003-05-12
CA2456604A1 (en) 2003-03-13
IL160375A0 (en) 2004-07-25
JP4636796B2 (ja) 2011-02-23
DK1425005T3 (da) 2006-09-04
CO5560554A2 (es) 2005-09-30
SI1425005T1 (sl) 2006-12-31
ECSP044986A (es) 2004-04-28
US20070231382A1 (en) 2007-10-04
DE60211183D1 (de) 2006-06-08
ES2263813T3 (es) 2006-12-16
DE60211183T2 (de) 2007-02-01
AU2002331094B2 (en) 2006-08-31
EP1425005A1 (de) 2004-06-09
RU2329801C2 (ru) 2008-07-27
ZA200400877B (en) 2004-11-01
US20030114527A1 (en) 2003-06-19
BR0212155A (pt) 2004-07-13
KR100895551B1 (ko) 2009-04-29
NO20040860L (no) 2004-04-22
RU2004109920A (ru) 2005-04-20
CA2456604C (en) 2011-02-08
CN1728993A (zh) 2006-02-01
AR036312A1 (es) 2004-08-25
HUP0401429A2 (hu) 2004-11-29
PT1425005E (pt) 2006-09-29
WO2003020261A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
FI20011478L (fi) Farmaseuttinen koostumus
DE60142197D1 (de) Pharmazeutische Zusammensetzung
DE60206889D1 (de) Pharmazeutische formulierung enthaltend bicalutamid
DE60213592D1 (de) Flüssige pharmazeutische zusammensetzung
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
NO20033556L (no) Farmasöytiske formuleringer
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
EE05020B1 (et) Glburiidi ravimkoostis
ATE320807T1 (de) Pharmazeutische zusammensetzungen enthaltend tegaserod
ATE324883T1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
IS7051A (is) Lyfjasamsetningar
FI20022128A0 (fi) Farmaseuttinen koostumus
ATE477814T1 (de) Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
ATE366128T1 (de) Pharmazeutische zusammensetzung
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
NO20033073L (no) Farmasöytisk sammensetning inneholdende citalopram
DE10107261B4 (de) Pharmazeutische Zusammensetzung
EP1413314A4 (de) Medizinische zusammensetzungen
FI5468U1 (fi) Farmaseuttinen koostumus
SE0100847D0 (sv) Novel pharmaceutical composition
SE0103565D0 (sv) Pharmaceutical formulation
SE0101325D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 1425005

Country of ref document: EP